NCT02515630View on ClinicalTrials.gov

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2016

Primary Completion Date

July 18, 2017

Study Completion Date

August 15, 2017

Conditions

Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis

Interventions

DRUG

MMB

Momelotinib (MMB) tablet administered orally once daily

Trial Locations (13)

Unknown

Phoenix

Los Angeles

Orange

Jacksonville

Baltimore

Ann Arbor

St Louis

New York

The Bronx

Durham

Cleveland

Houston

Toronto

All Listed Sponsors

lead

Sierra Oncology LLC - a GSK company

INDUSTRY

NCT02515630 - Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | Biotech Hunter | Biotech Hunter